Marathon Asset Management (UK)’s Bio-Rad Laboratories Class A BIO Stock Holding History

Marathon Asset Management (UK)’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.3M	Sell	41,975 -11,686	-22%	-$3.31M	0.5%	57
2026 Q1	$15M	Buy	53,661 +6,369	+13%	+$1.83M	0.57%	56
2025 Q4	$14.3M	Sell	47,292 -4,626	-9%	-$1.44M	0.55%	49
2025 Q3	$14.6M	Sell	51,918 -7,893	-13%	-$2.15M	0.54%	48
2025 Q2	$14.4M	Sell	59,811 -844	-1%	-$200K	0.46%	58
2025 Q1	$14.8M	Sell	60,655 -6,472	-10%	-$1.95M	0.45%	55
2024 Q4	$22.1M	Sell	67,127 -4,410	-6%	-$1.5M	0.62%	45
2024 Q3	$23.9M	Buy	71,537 +344	+0.5%	+$109K	0.66%	48
2024 Q2	$19.4M	Sell	71,193 -4,664	-6%	-$1.36M	0.61%	57
2024 Q1	$26.2M	Buy	+75,857	New	+$24.9M	0.7%	48

Other funds holding BIO

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Marathon Asset Management (UK)'s BIO Position: Q2 2026 in Review

Marathon Asset Management (UK) reduced its Bio-Rad Laboratories Class A (BIO) stake by 22% in Q2 2026, selling an estimated $3.31M and leaving 41,975 shares worth $12.3M. The position accounts for 0.5% of the portfolio, ranked #57.

Marathon Asset Management (UK) first reported a position in BIO in Q1 2024 and has held it in 10 quarters since. The position peaked at $26.2M in Q1 2024. 398 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

Marathon Asset Management (UK) held 41,975 shares of Bio-Rad Laboratories Class A worth $12.3M as of Q2 2026.
Marathon Asset Management (UK) sold 11,686 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $3.31M.
Bio-Rad Laboratories Class A made up 0.5% of Marathon Asset Management (UK)'s portfolio in Q2 2026, its #57 holding.
Marathon Asset Management (UK) first reported a position in Bio-Rad Laboratories Class A in Q1 2024 and has held it in 10 quarters since.
Marathon Asset Management (UK)'s Bio-Rad Laboratories Class A position peaked at $26.2M in Q1 2024.
398 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Marathon Asset Management (UK)'s 13F filing for Q2 2026, filed 14 Aug 2026.